NLRP3 Inflammasome: Key Regulatory Molecules in Acute Liver Injury and Advances in Targeted Therapeutics
Keywords:
NLRP3 inflammasome, Acute liver injury, Inflammatory regulation, Targeted interventionAbstract
Acute liver injury refers to hepatocyte damage and abnormal liver function triggered by various factors such as infection, drugs, toxins, and immune abnormalities, with its pathological process closely associated with inflammatory responses. The NLRP3 inflammasome, as a crucial intracellular pattern recognition receptor complex, plays a central role in mediating inflammatory responses and regulating pyroptosis. Recent studies confirm that NLRP3 inflammasome activation serves as a pivotal link between liver injury triggers and the inflammatory cascade, with its activation level directly influencing injury severity and prognosis. This paper systematically reviews the structure, function, and activation mechanisms of the NLRP3 inflammasome. It focuses on elucidating the role and mechanism of the NLRP3 inflammasome in different types of acute liver injury and summarizes intervention strategies targeting the NLRP3 inflammasome, providing a theoretical basis for the clinical treatment of acute liver injury.
References
Hao, H., & Jiang, R. (in press). Effects of gut microbiota on explosive hepatitis based on animal models. Journal of Jiangsu University (Medical Edition).
Wang, X., & Wang, Q. (2015). Advances in research on the correlation between NLRP3 inflammasome and diabetic nephropathy. Journal of Medical Research, 44(5), 180–182.
Liu, S., Yao, D., Zhang, Y., et al. (2022). Mechanism study of distant ischemia preconditioning improving inflammatory injury in rat cerebral ischemia/reperfusion via regulating mitochondrial membrane potential. Advances in Anatomical Sciences, 28(6), 694–698.
Bao, S., You, S., & Li, X. (2021). Research progress on inflammatory markers in myocardial infarction. Modern Medicine and Health, 37(18), 3118–3122.
Wen, Z., & Tang, Z. (2014). Research progress on NLRP6. Chinese Journal of Clinicians (Electronic Edition), 8(15), 2847–2851.
Wang, W. (2012). Expression of NLRP3 inflammasome in renal tubular epithelial cells cultured with high glucose and its relationship with apoptosis [Master's thesis, Shanxi Medical University].
Li, J., Qi, X., & Li, J. (2018). Research progress on NLRP3 inflammasome and gout. Advances in Modern Biomedical Sciences, 18(2), 364–368.
Chen, Z., Tang, C., & Xu, W. (2025). Research progress on NLRP3 inflammasome affecting intervertebral disc degeneration. Zhejiang Clinical Medicine, 27(10), 1578–1580.
Li, X., Bai, Y., Wang, Y., et al. (2023). Research progress on nucleotide-binding oligomerization domain-like receptor 3 inflammasome in post-stroke cognitive impairment. Chinese General Practice, 26(17), 2176–2182.
Wang, H., Hu, W., Wang, X., et al. (2025). Protective effects and mechanisms of geniposidic acid in preventing acetaminophen-induced drug-induced liver injury. Chinese Journal of Pharmacology, 41(4), 709–717.
Wu, M., Jin, H., Li, K., et al. (2023). Research progress on mitochondrial mechanisms of acetaminophen-induced liver injury. Chinese Journal of Pharmacology and Toxicology, 37(5), 393–400.
Yuan, X. (2024). *Study on the role of NLRP3 in acetaminophen-induced acute liver injury in mice via regulation of hepatocyte pyroptosis* [Master's thesis, Qingdao University].
Li, J., Wang, R., Zhang, Y., et al. (2022). Study on the mechanism of emodin ether in alleviating drug-induced liver injury via the HMGB1-NLRP3 signaling pathway. Chinese Herbal Drugs, 53(7), 2095–2102.
Andersson, U., & Tracey, K. J. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annual Review of Immunology, 29, 139–162.
Lundbäck, P., Lea, J. D., Sowinska, A., et al. (2016). A novel high mobility group box 1 neutralizing chimeric antibody attenuates drug-induced liver injury and postinjury inflammation in mice. Hepatology, 64(5), 1699–1710.
Deng, J. (2025). Mechanism of action of Triphyllum inosum in treating antituberculosis drug-induced liver injury based on the ROS/GSDMD signaling pathway [Master's thesis, Guangxi University of Chinese Medicine].
Luan, J., Zhang, X., Wang, S., et al. (2018). NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated ConA-induced hepatitis. Frontiers in Immunology, 9, 758.
Hao, Y. F., Lu, Y. Y., Wang, X. L., et al. (2020). Protective effects of gentiopicroside on concanavalin A (ConA)-induced liver injury in mice and its mechanism. Journal of Yantai University (Natural Science and Engineering Edition), 33(2), 168–174.
Li, Y. (2023). *Mechanism of Lewis lung cancer and/or PD-1 antibody aggravating immune hepatitis in mice and the interventional effect of ginsenoside Rd* [Doctoral dissertation, Jilin University].
Geng, J., Liu, Q., Xiong, X., et al. (2025). Advances in research on the correlation between hepatitis B virus and hepatocellular carcinoma development. Liver, 30(3), 403–407.
Zhang, Z. (2023). *Mechanism study of HBV-hijacked exosomes suppressing M1 macrophages to promote immune escape* [Master's thesis, North Sichuan Medical College].
Li, J., Zhang, C., & Huo, R. (2025). Protective effects and mechanisms of paeoniflorin against HBV-induced liver tissue damage in mice. Anhui Medicine, 29(1), 39–43+213.
Xie, W. (2019). Mechanism of HBx activating NLRP3 inflammasome to induce hepatocyte inflammation and pyroptosis under oxidative stress [Master's thesis, Fujian Medical University].
Shen, Y., Chen, D., Linghu, M., et al. (2024). MLKL deficiency alleviates acute alcoholic liver injury via inhibition of NLRP3 inflammasome. Toxicology, 506, 153864.
Feng, H. (2020). *Protective effects of Ficus benjamina on acute alcoholic liver injury in mice via the Keap1-Nrf2/ARE pathway* [Master's thesis, Guangzhou University of Chinese Medicine].
Xu, Z., Tan, Y., Zhang, Q., et al. (2023). Effects of Pien Tze Huang on autophagy and NLRP3 inflammasome activation in alcohol-induced acute liver injury in mice. Chinese Journal of Pharmaceutical Research, 42(8), 537–542.
Mu, W., Xu, G., Wei, Z., et al. (2022). The role of NLRP3 inflammasome in psychotropic drug-induced hepatotoxicity. Cell Death Discovery, 8(1), 313.
Liu, J., Liu, Y., Zhang, B., et al. (2022). Mechanism study of NLRP3 inflammasome inhibitor MCC950 in improving non-alcoholic steatohepatitis formation. Chinese Journal of Modern Surgery, 25(6), 421–425.
Wang, Q., Wei, S., Zhou, S., et al. (2020). Hyperglycemia aggravates acute liver injury by promoting liver-resident macrophage NLRP3 inflammasome activation via the inhibition of AMPK/mTOR-mediated autophagy induction. Immunology and Cell Biology, 98(1), 54–66.
Marchetti, C., Swartzwelter, B., Gamboni, F., et al. (2018). OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proceedings of the National Academy of Sciences of the United States of America, 115(7), E1530–E1539.
Ilyas, G., Cingolani, F., Zhao, E., et al. (2019). Decreased macrophage autophagy promotes liver injury and inflammation from alcohol. Alcoholism: Clinical and Experimental Research, 43(7), 1403–1413.
Ratziu, V., Sheikh, M. Y., Sanyal, A. J., et al. (2012). A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology, 55(2), 419–428.
Wu, Y. L., Ou, W. J., Zhong, M., et al. (2022). Gasdermin D inhibitor necrosulfonamide alleviates lipopolysaccharide/ D-galactosamine-induced acute liver failure in mice. Journal of Clinical and Translational Hepatology, 10(6), 1148–1154.
Zhang, J., Feng, Q. Y., Sun, H. M., et al. (2024). Mechanism of ginsenoside Rc in modulating P2X7r-NLRP3 signaling pathway to improve alcoholic liver disease. Journal of Beihua University (Natural Science Edition), 25(6), 744–748.
Song, C., Fu, C., Huangfu, H., et al. (2023). Effects of curcumin on oxidative stress and NLRP3 inflammasome activation in corn zearalenone-treated mouse liver. Chinese Journal of Veterinary Science, 43(9), 1898–1904.
Zhou, Y., Que, R., Li, Y., et al. (2020). Effects of resveratrol on NLRP3 inflammasome expression in mice with acute liver injury. World Clinical Drugs, 41(2), 104–110+142.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Yulei Gou, Jie Xiao, Yu Fan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
